Jefferson Outreach Program Department of Psychiatry - Philadelphia Pennsylvania

Jefferson Outreach Program Department of Psychiatry - Philadelphia, PA

Jefferson Outreach Program Department Of Psychiatry is treatment facility located at 833 Chestnut Street East, Suite 210-e in the 19107 zip code in Philadelphia, PA that offers medication-assisted substance use treatment. Jefferson Outreach Program Department Of Psychiatry provides suboxone prescription and buprenorphine maintenance to young adults and adults. Some of the treatment approaches used by Jefferson Outreach Program Department Of Psychiatry consist of cognitive behavioral therapy, 12-step facilitation and relapse prevention.

Address: 833 Chestnut Street East, Suite 210-E, Philadelphia, PA 19107

1. Types of Care
2. Service Settings
3. Opioid Medications used in Treatment
4. External Opioid Medications Source
5. Type of Alcohol Use Disorder Treatment
6. Type Of Treatment
7. Pharmacotherapies
8. Treatment Approaches
9. FacilityOwnership
10. License/Certification/Accreditation
11. Payment/Insurance/Funding Accepted
12. Payment Assistance Available
13. Assessment/Pre-treatment
14. Screening & Testing
15. Transitional Services
16. Ancillary Services
17. Counseling Services and Education
18. Tobacco/Screening Services
19. Facility Smoking Policy
20. Age Groups Accepted
21. Gender Accepted
22. Services for deaf

Here are the full facility listing details on Jefferson Outreach Program Department of Psychiatry in Philadelphia, PA:

Phone #: 215-503-2823

Is Methadone a safe option for addiction treatment?

Methadone treatment can be a safe and effective option for individuals struggling with opioid addiction, especially when administered under the supervision of a qualified healthcare provider as part of a comprehensive addiction treatment program, such as the one that can be found at Jefferson Outreach Program Department of Psychiatry. Methadone is an opioid medication that is used to help manage opioid withdrawal symptoms and cravings, making it easier for individuals to reduce or quit their use of other opioids like heroin or prescription painkillers.

Here are some key points to consider regarding the safety of methadone treatment:

1. Supervised Administration: Methadone treatment is typically provided through opioid treatment programs (OTPs) or clinics where patients receive a daily dose of methadone under the supervision of healthcare professionals. This helps reduce the risk of misuse and overdose.

2. Reduces Withdrawal Symptoms: Methadone can alleviate the severe withdrawal symptoms associated with opioids, which can be a significant barrier to recovery. This can enhance the patient's quality of life and make it easier for them to engage in therapy and counseling.

3. Harm Reduction: Methadone maintenance treatment can be viewed as a harm reduction approach. While it doesn't necessarily lead to immediate abstinence, it reduces the risks associated with illicit opioid use, such as overdose and the transmission of infectious diseases (e.g., HIV and hepatitis).

4. Individualized Treatment: Methadone treatment should be individualized to meet the unique needs of each patient. The dose is typically adjusted based on the patient's response and progress in treatment.

5. Legal Regulation: Methadone clinics and providers are subject to strict regulations and oversight by government agencies to ensure safety and appropriate use of the medication.

However, it's important to note that methadone is an opioid itself and can be habit-forming. When taken as prescribed and under medical supervision, the risk of addiction to methadone is relatively low. However, misuse or diversion of methadone can lead to addiction and other negative consequences.

Methadone treatment is not suitable for everyone. Individuals with certain medical conditions or contraindications may not be candidates for methadone treatment. It's essential for addiction treatment centers like Jefferson Outreach Program Department of Psychiatry to conduct a thorough assessment before starting someone on methadone.